Gelderblom, H., Bhadri, V., Stacchiotti, S., Bauer, S., Wagner, A. J., van de Sande, M., . . . Ravi, V. (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet (British edition), 403(10445), 2709-2719. https://doi.org/10.1016/S0140-6736(24)00885-7
Chicago-Zitierstil (17. Ausg.)Gelderblom, Hans, et al. "Vimseltinib Versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition) 403, no. 10445 (2024): 2709-2719. https://doi.org/10.1016/S0140-6736(24)00885-7.
MLA-Zitierstil (9. Ausg.)Gelderblom, Hans, et al. "Vimseltinib Versus Placebo for Tenosynovial Giant Cell Tumour (MOTION): A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet (British Edition), vol. 403, no. 10445, 2024, pp. 2709-2719, https://doi.org/10.1016/S0140-6736(24)00885-7.